Janssen Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH139720D
- Pages: 96
- November 2018
- Total Views:1122
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women's health, and others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer's disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. It caters services to cardiovascular & metabolism, immunology, infectious diseases, vaccines, neuroscience,Oncology and other therapeutic areas. Janssen is headquartered in Titusville, New Jersey, the US.
Janssen Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Venture Financing 19
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19
Partnerships 20
Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24
Janssen Pharma Enters into Research Partnership with Beacon Discovery 25
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26
Genomic Health Enters into Research Agreement with Janssen Pharma 27
Cerveau Technologies Enters into Agreement with Janssen Pharma 28
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29
PeptiDream Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Partnership with Premier 31
Renova Therapeutics Enters into Agreement with Janssen Pharma 32
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33
Karolinska Institutet Partners with Johnson & Johnson Companies 34
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35
Janssen Pharma Enters into Partnership with Bird Rock Bio 36
DiamiR Enters into Research Agreement with Janssen Pharma 37
Janssen Pharma Enters into Agreement with University of Pennsylvania 38
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40
Janssen Pharma Enters into Agreement with University of California, San Diego 41
Cypralis Enters into Research Agreement with Janssen Pharma 42
BlinkBio Enters into Discovery Agreement with Janssen Pharma 43
NeurOp Enters into Research Agreement with Janssen Pharma 44
AC Immune Enters into Research Agreement with Janssen Pharma 45
Alector Enters Into Research Agreement With Janssen Pharma 46
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48
Mellitech Enters into Agreement with Janssen Pharma 50
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52
Licensing Agreements 53
Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53
Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62
AC Immune Enters into Licensing Agreement with Janssen Pharma 63
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66
Janssen Pharma Enters into Licensing Agreement with BiocerOX 67
Orion Enters Into Licensing Agreement With Janssen Pharma 68
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72
Shionogi Enters Into Licensing Agreement With Janssen Pharma 74
Depomed Enters Into Licensing Agreement With Janssen Pharma 75
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78
Asset Transactions 80
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81
Vivus Acquires Topiramate Related Patents from Janssen Pharma 83
Acquisition 84
Janssen Pharma Acquires XO1 84
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85
Janssen Pharmaceuticals Inc-Key Competitors 87
Janssen Pharmaceuticals Inc-Key Employees 88
Janssen Pharmaceuticals Inc-Locations And Subsidiaries 89
Head Office 89
Other Locations & Subsidiaries 89
Recent Developments 90
Strategy And Business Planning 90
Oct 05, 2018: Janssen signs USD 3.7bn worth licence agreements with Arrowhead 90
Legal and Regulatory 91
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 91
Government and Public Interest 92
Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 92
Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 93
Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 94
Other Significant Developments 95
Oct 09, 2017: Johnson & Johnson investing USD 350M in EU biologics operation, adding 200 jobs 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
List Of Figure
List of Figures
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19
Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24
Janssen Pharma Enters into Research Partnership with Beacon Discovery 25
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26
Genomic Health Enters into Research Agreement with Janssen Pharma 27
Cerveau Technologies Enters into Agreement with Janssen Pharma 28
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29
PeptiDream Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Partnership with Premier 31
Renova Therapeutics Enters into Agreement with Janssen Pharma 32
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33
Karolinska Institutet Partners with Johnson & Johnson Companies 34
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35
Janssen Pharma Enters into Partnership with Bird Rock Bio 36
DiamiR Enters into Research Agreement with Janssen Pharma 37
Janssen Pharma Enters into Agreement with University of Pennsylvania 38
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40
Janssen Pharma Enters into Agreement with University of California, San Diego 41
Cypralis Enters into Research Agreement with Janssen Pharma 42
BlinkBio Enters into Discovery Agreement with Janssen Pharma 43
NeurOp Enters into Research Agreement with Janssen Pharma 44
AC Immune Enters into Research Agreement with Janssen Pharma 45
Alector Enters Into Research Agreement With Janssen Pharma 46
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48
Mellitech Enters into Agreement with Janssen Pharma 50
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52
Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53
Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62
AC Immune Enters into Licensing Agreement with Janssen Pharma 63
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66
Janssen Pharma Enters into Licensing Agreement with BiocerOX 67
Orion Enters Into Licensing Agreement With Janssen Pharma 68
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72
Shionogi Enters Into Licensing Agreement With Janssen Pharma 74
Depomed Enters Into Licensing Agreement With Janssen Pharma 75
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81
Vivus Acquires Topiramate Related Patents from Janssen Pharma 83
Janssen Pharma Acquires XO1 84
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85
Janssen Pharmaceuticals Inc, Key Competitors 87
Janssen Pharmaceuticals Inc, Key Employees 88
Janssen Pharmaceuticals Inc, Other Locations 89
Janssen Pharmaceuticals Inc, Subsidiaries 89
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Company Profile
Company Profile Title
Summary
Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women's health, and others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer's disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. It caters services to cardiovascular & metabolism, immunology, infectious diseases, vaccines, neuroscience,Oncology and other therapeutic areas. Janssen is headquartered in Titusville, New Jersey, the US.
Janssen Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Venture Financing 19
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19
Partnerships 20
Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24
Janssen Pharma Enters into Research Partnership with Beacon Discovery 25
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26
Genomic Health Enters into Research Agreement with Janssen Pharma 27
Cerveau Technologies Enters into Agreement with Janssen Pharma 28
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29
PeptiDream Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Partnership with Premier 31
Renova Therapeutics Enters into Agreement with Janssen Pharma 32
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33
Karolinska Institutet Partners with Johnson & Johnson Companies 34
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35
Janssen Pharma Enters into Partnership with Bird Rock Bio 36
DiamiR Enters into Research Agreement with Janssen Pharma 37
Janssen Pharma Enters into Agreement with University of Pennsylvania 38
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40
Janssen Pharma Enters into Agreement with University of California, San Diego 41
Cypralis Enters into Research Agreement with Janssen Pharma 42
BlinkBio Enters into Discovery Agreement with Janssen Pharma 43
NeurOp Enters into Research Agreement with Janssen Pharma 44
AC Immune Enters into Research Agreement with Janssen Pharma 45
Alector Enters Into Research Agreement With Janssen Pharma 46
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48
Mellitech Enters into Agreement with Janssen Pharma 50
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52
Licensing Agreements 53
Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53
Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62
AC Immune Enters into Licensing Agreement with Janssen Pharma 63
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66
Janssen Pharma Enters into Licensing Agreement with BiocerOX 67
Orion Enters Into Licensing Agreement With Janssen Pharma 68
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72
Shionogi Enters Into Licensing Agreement With Janssen Pharma 74
Depomed Enters Into Licensing Agreement With Janssen Pharma 75
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78
Asset Transactions 80
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81
Vivus Acquires Topiramate Related Patents from Janssen Pharma 83
Acquisition 84
Janssen Pharma Acquires XO1 84
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85
Janssen Pharmaceuticals Inc-Key Competitors 87
Janssen Pharmaceuticals Inc-Key Employees 88
Janssen Pharmaceuticals Inc-Locations And Subsidiaries 89
Head Office 89
Other Locations & Subsidiaries 89
Recent Developments 90
Strategy And Business Planning 90
Oct 05, 2018: Janssen signs USD 3.7bn worth licence agreements with Arrowhead 90
Legal and Regulatory 91
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 91
Government and Public Interest 92
Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 92
Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 93
Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 94
Other Significant Developments 95
Oct 09, 2017: Johnson & Johnson investing USD 350M in EU biologics operation, adding 200 jobs 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
List Of Figure
List of Figures
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19
Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24
Janssen Pharma Enters into Research Partnership with Beacon Discovery 25
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26
Genomic Health Enters into Research Agreement with Janssen Pharma 27
Cerveau Technologies Enters into Agreement with Janssen Pharma 28
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29
PeptiDream Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Partnership with Premier 31
Renova Therapeutics Enters into Agreement with Janssen Pharma 32
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33
Karolinska Institutet Partners with Johnson & Johnson Companies 34
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35
Janssen Pharma Enters into Partnership with Bird Rock Bio 36
DiamiR Enters into Research Agreement with Janssen Pharma 37
Janssen Pharma Enters into Agreement with University of Pennsylvania 38
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40
Janssen Pharma Enters into Agreement with University of California, San Diego 41
Cypralis Enters into Research Agreement with Janssen Pharma 42
BlinkBio Enters into Discovery Agreement with Janssen Pharma 43
NeurOp Enters into Research Agreement with Janssen Pharma 44
AC Immune Enters into Research Agreement with Janssen Pharma 45
Alector Enters Into Research Agreement With Janssen Pharma 46
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48
Mellitech Enters into Agreement with Janssen Pharma 50
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52
Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53
Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62
AC Immune Enters into Licensing Agreement with Janssen Pharma 63
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66
Janssen Pharma Enters into Licensing Agreement with BiocerOX 67
Orion Enters Into Licensing Agreement With Janssen Pharma 68
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72
Shionogi Enters Into Licensing Agreement With Janssen Pharma 74
Depomed Enters Into Licensing Agreement With Janssen Pharma 75
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81
Vivus Acquires Topiramate Related Patents from Janssen Pharma 83
Janssen Pharma Acquires XO1 84
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85
Janssen Pharmaceuticals Inc, Key Competitors 87
Janssen Pharmaceuticals Inc, Key Employees 88
Janssen Pharmaceuticals Inc, Other Locations 89
Janssen Pharmaceuticals Inc, Subsidiaries 89
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020